HealthCap, a leading life science venture capital firm, has opened office in the newly established incubator in the Oslo Cancer Cluster Innovation Park. HealthCap also becomes a member of the Oslo Cancer Cluster.
HealthCap recognizes the emerging life sciences industry in Norway. "The strong environment created in the dedicated oncology cluster, bringing together all parts of the oncology value chain at the world renowned Radiumhospitalet, holds promise to play an important role in the development of the next generations of oncology treatments. We look forward to take part in and contribute to this important endeavor", says Björn Odlander, managing partner of HealthCap.
HealthCap has retained Ludvik Sandnes to supervise the Norwegian operations. Ludvik Sandnes is a special advisor to HealthCap and has more than 40 years of experience from international corporate finance and asset management. He is currently the chairman of the listed Norwegian oncology company Nordic Nanovector AS.
HealthCap will host a seminar at the Oslo Cancer Cluster Innovation Park on December 9th at 12.30.
Please sign up here, the program will be published shortly.
The CEO of Oslo Cancer Cluster and Chairman of the Board of Oslo Cancer Cluster Incubator, Ketil Widerberg says "We are extremely happy to have HealthCap on board both in the Oslo Cancer Cluster and in the Incubator. HealthCap´s track record of investing in life science is impressing, and their competence and network will be valuable for further building a viable oncology industry based on excellent cancer research at Norwegian academic institutions."
HealthCap invests in companies developing targeted therapies for rare diseases, cancer and genetic diseases, among others. HealthCap was the lead investor in the Norwegian oncology company Algeta, which was acquired by Bayer for USD 2.9 bn, and is the largest shareholder in the Norwegian oncology companies Nordic Nanovector AS and Targovax AS.
Purely focused on oncology, the Oslo Cancer Cluster Innovation Park and Incubator, will ensure that bright ideas in the lab benefit cancer patients faster than today.